All
Stereotactic Body Radiotherapy with Immune Checkpoint Inhibitors Ineffective as Treatment for Solid Tumors
A randomized clinical trial, CHEERS, determined that the combination of stereotactic body radiotherapy (SBRT) and immune checkpoint inhibitors (ICIs) were ineffective as treatment for patients with advanced solid tumors.
New Drugs Being Explored in Kidney Cancer
An expert gives an overview of up-and-coming treatments for patients with kidney cancer.
Drug Duo Continues to Show Promise in Advanced Kidney Cancer
Long-term follow-up data showed that Lenvima plus Keytruda continued to show benefit in patients with metastatic kidney cancer.
Upfront Immunotherapy Delays Surgery, Improves Metastatic Kidney Cancer Control
Immunotherapy combinations tended to improve outcomes for patients with metastatic kidney cancer who go on to receive surgery.
A Few Lasting Side Effects That Aren't So Bad
I couldn't believe that I would benefit from some of the side effects of my cancer treatment.
Radiation Effective, Does Not Worsen Quality of Life in Kidney Cancer
Radiation is an emerging treatment modality in kidney cancer. Research shows that it is effective and helps patients maintain a good quality of life.
Keytruda Prolongs Time Without Cancer Signs, Symptoms in Clear Cell RCC
Keytruda after nephrectomy improved disease-free survival rates in patients with clear cell renal cell carcinoma regardless of disease risk or stage.
Lenvima, Keytruda Elicits Greater Responses Than Sutent in Advanced RCC
Responses to treatment with Lenvima plus Keytruda for advanced renal cell carcinoma were present regardless of PD-L1 status.
A Wee Problem: Another Chemo Side Effect They Didn’t Tell Me About
One side effect of chemotherapy that no one warned me about was frequent urination.
Dick Vitale Announces Vocal Cord Cancer Diagnosis, Andrea Evans Dies from Breast Cancer and More
From Stand Up to Cancer honoring survivors at a Minor League baseball game, to Maria Menounos showing her cancer scars on Instagram, here’s what’s happening in the oncology space this week.
Treatments, Patient Characteristics Affect Uveal Melanoma Survival
A new study identified the elements that could determine the overall survival of patients with the metastatic eye tumor, uveal melanoma.
Insurance Type May Indicate Survival Outcomes in Metastatic RCC
Patients with Medicaid or no insurance may have worse survival outcomes compared with Medicare or private insurance in those with metastatic renal cell carcinoma.
Navigating the Benefits, Access to Palliative Care for Advanced Cancer
Palliative care can benefit patients with advanced cancer by integrating advanced care planning, pain and symptom management and counseling, among other aspects.
Adjusting to Incorporate Cancer Into Life
After being diagnosed with cancer, I experienced the fear of missing out, but eventually replaced it with the joy of missing out.
Is it OK to Just Put a Sticker on It When It Comes to Cancer and Other Health Issues?
When it comes to a physical exam, you don’t know how much of an impact it could make.
Latinas Contra Cancer ‘Holds Space for Patients to Become Powerful’
Darcie Green, executive director of service and advocacy organization Latinas Contra Cancer, tells the CURE® “Cancer Horizon” podcast about how its work has broadened over the last 20 years.
Pre-Chemo Laparoscopy Can Help Determine Pancreatic Cancer Treatment
Staging a laparoscopy can help patients with pancreatic cancer identify the stage of cancer, where it spread and what the best treatment may be, a recent study shows.
Breyzani Benefits Previously Treated SLL, CLL
CAR T-cell therapy positively benefitted patients with patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
FDA Reviewing Brukinsa Combo for Relapsed/Refractory Follicular Lymphoma
The Food and Drug Administration accepted a supplemental New Drug Application for Brukinsa plus Gazyva to treat patients with relapsed or refractory follicular lymphoma.
Perceptions and Reflections on My Cancer Diagnosis
Looking back on the nine years since being diagnosed with breast cancer, here are my perceptions and reflections of the disease.
Grief and Gratitude
I think it was Theodore Geisel (aka Dr Seuss) who said “Don’t cry because it’s over, smile because it happened.”
Writing ‘Taught Me to Become’ After Cancer
Writing about my breast cancer experience became cathartic to me, and eventually my journal entries were compiled into a book, “Feisty Righty.”
Radiotherapy Method Can Cut Treatment Time, Maintain Breast Cancer Control
Treatment time for patients with early-detected breast cancer may be reduced by one week with the use of simulated integrated boost (SIB) radiotherapy.
Heart-Related Toxicities May Still Occur in AYAs With Kidney Cancer
Adolescents and young adults undergoing VEGF treatment for nonmetastatic, high-risk renal cell carcinoma may still experience heart-related conditions like left ventricular systolic dysfunction and high blood pressure.
Opdivo Plus Chemo Provides Survival Benefit in Bladder Cancer Subtype
Immunotherapy with Opdivo plus cisplatin-based chemotherapy improved overall survival and progression-free survival in patients with unresectable or metastatic urothelial carcinoma.
How My Nurses Dragged Me Across the Cancer Finish Line
I remember my first trip to the “chemo room”.
Discuss Symptoms, Other Health Issues for the Best MPN Treatment
Disease symptoms, as well as other health conditions, can have a major impact on the treatment plan for patients with myeloproliferative neoplasms.
VEGF Inhibitor Improves Survival in Previously Treated Metastatic CRC
Fruquintinib improved overall survival compared with placebo in patients with refractory metastatic colorectal cancer.
Five Years of Metastatic Breast Cancer: My Survival Stats
The statistics for metastatic are grim, so I made a list of my own numbers instead.
Inflammation May Affect Depression, Activity, Regardless of Cancer
While inflammation may not be associated with certain cancer-related symptoms, it can impact depression and physical activity levels in anyone, recent research showed.